Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
17.40M | 17.52M | 23.52M | 16.77M | 15.64M | 22.34M | Gross Profit |
8.91M | 10.36M | 13.18M | 10.01M | 11.27M | 16.54M | EBIT |
-3.06M | -1.96M | 732.00K | -529.00K | 2.51M | 3.97M | EBITDA |
-1.26M | 45.00K | 2.09M | 598.00K | 2.26M | 5.59M | Net Income Common Stockholders |
-2.74M | -1.99M | 862.00K | -1.10M | 37.00K | 1.85M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
8.59M | 9.38M | 8.24M | 11.33M | 14.28M | 9.27M | Total Assets |
27.57M | 24.60M | 28.48M | 28.92M | 26.83M | 26.84M | Total Debt |
4.41M | 1.25M | 1.61M | 2.87M | 1.23M | 1.55M | Net Debt |
-4.18M | -8.13M | -6.63M | -8.46M | -13.05M | -7.72M | Total Liabilities |
8.56M | 5.78M | 7.39M | 8.40M | 5.70M | 5.73M | Stockholders Equity |
19.01M | 18.82M | 21.10M | 20.53M | 21.13M | 21.11M |
Cash Flow | Free Cash Flow | ||||
-761.00K | 1.94M | -1.25M | -1.94M | 5.55M | 5.09M | Operating Cash Flow |
1.09M | 2.08M | -1.02M | -1.60M | 5.61M | 5.31M | Investing Cash Flow |
-1.77M | -133.00K | -290.00K | -846.00K | -59.00K | -215.00K | Financing Cash Flow |
-879.00K | -782.00K | -1.85M | -500.00K | -476.00K | -4.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | C$322.89M | ― | -0.53% | 5.17% | -21.32% | 82.85% | |
63 Neutral | C$124.63M | ― | -24.49% | ― | -8.60% | 21.06% | |
54 Neutral | C$10.86M | ― | -15.57% | ― | -7.56% | -334.57% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
40 Underperform | $100.24M | ― | ― | 6.07% | 80.33% |
Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.